Amgen today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended median overall ...

We are pleased to share the May 2025 issue of Wilson Sonsini’s Sustainability and ESG Advisory Practice Update. Each issue combines news, key ...

There’s a profound difference between depriving yourself—believing certain foods are off-limits because they’re “bad”—and ...

Roaches played a role in the temporarily closure of one cafe, and a few other inspections that failed to meet standards.

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers rega ...

About itepekimab Itepekimab is a fully human monoclonal antibody that binds to and inhibits interleukin-33 (IL33), an initiator and amplifier of broad inflammation in COPD. IL33 is thought to be ...

Snorkel AI announced general availability of two new product offerings on the Snorkel AI Data Development Platform: Snorkel Evaluate and Snorkel Expert Data-as-a-Service. These launches advance its ...

Q1 2025 highlighted the growing traction of the company's data collection solutions with leading AI and eCommerce players worldwide Company ...

The bills come amid a national effort, led by U.S. Health and Human Services Secretary Robert F. Kennedy Jr., to overhaul ...

After calling out big food brands for falsely claiming that their products were healthy, Himatsingka is ready for the next ...

We highlighted the substantive changes made by House Republicans to secure the support of several holdout members.

Recent FDA updates in the areas of cardiac intervention, hypertension and arrhythmia disorders expand the pool of available ...